Overview

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

Status:
Completed
Trial end date:
2016-07-15
Target enrollment:
Participant gender:
Summary
This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Crizotinib